Morningside’s Big Buy Spurs Confidence as Apnimed Shakes Off Debt‑Heavy Roots Ahead of Sleep‑Therapy Push
Apnimed’s IPO surge: Morningside buys 6.84M shares, boosting liquidity and backing the sleep‑disorder drug pipeline. Watch post‑IPO momentum.
4 minutes to read